Compare EVGO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | IMMP |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.6M | 42.4M |
| IPO Year | 2020 | 2012 |
| Metric | EVGO | IMMP |
|---|---|---|
| Price | $1.36 | $4.74 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | $5.23 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 3.4M | 341.9K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,588,000.00 | N/A |
| Revenue This Year | $16.45 | $445.09 |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 145.74 | N/A |
| 52 Week Low | $1.23 | $0.26 |
| 52 Week High | $5.18 | $5.36 |
| Indicator | EVGO | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 92.30 |
| Support Level | $1.23 | $2.65 |
| Resistance Level | $1.53 | N/A |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.00 | 0.44 |
| Stochastic Oscillator | 22.29 | 85.50 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.